Olr336 inhibitors represent a specialized class of chemical compounds that specifically target the Olr336 receptor, a member of the olfactory receptor (OR) family. The Olr336 receptor is a G protein-coupled receptor (GPCR) that is primarily involved in the detection and transduction of odorant molecules, contributing to the complex sensory process of olfaction. These receptors, like other GPCRs, span the cellular membrane and upon activation by specific ligands, initiate a signaling cascade that ultimately leads to a physiological response. In the case of Olr336, this response is associated with the recognition of particular volatile compounds, which play a role in the perception of scents. The inhibition of the Olr336 receptor is of interest in chemical and biochemical research due to its potential to modulate olfactory signaling pathways.
The design and synthesis of Olr336 inhibitors involve an intricate understanding of the receptor's binding site and the molecular interactions that occur between the receptor and its natural ligands. Researchers focus on creating compounds that can effectively block these interactions, thereby preventing the receptor from activating its downstream signaling pathways. This inhibition can be achieved through various chemical strategies, including the use of competitive antagonists that mimic the natural ligands of Olr336 but do not trigger receptor activation. Structural biology, particularly techniques such as X-ray crystallography and molecular docking, plays a crucial role in identifying the binding conformations of these inhibitors and optimizing their efficacy. The study of Olr336 inhibitors not only contributes to the broader understanding of GPCR function but also opens avenues for exploring how olfactory signaling can be modulated at a molecular level.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity potentially affecting Olr336. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, could influence Olr336 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, may affect GPCR signaling pathways related to Olr336. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $176.00 | ||
Combined alpha and beta blocker, could indirectly affect GPCR pathways including Olr336. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr336. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olr336 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr336. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr336. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr336. |